1-20 of 61
hodgkin's disease
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Evidence-Based Minireview: What is the optimal timing of anti–PD-1 antibodies in relapsed classical Hodgkin lymphoma?

Pamela Blair Allen, Ann S. LaCasce
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 249–251.
https://doi.org/10.1182/hematology.2019000077
Published: 2019
Journal Articles

Management of older Hodgkin lymphoma patients

Andrew M. Evens, Jordan Carter, Kah Poh Loh, Kevin A. David
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 233–242.
https://doi.org/10.1182/hematology.2019000028
Published: 2019
Journal Articles

Novel agents and immune invasion in Hodgkin lymphoma

Reid W. Merryman, Ann LaCasce
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 243–248.
https://doi.org/10.1182/hematology.2019000029
Published: 2019
Journal Articles

Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment

Scott F. Huntington
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 252–259.
https://doi.org/10.1182/hematology.2019000030
Published: 2019
Journal Articles

Where does PD-1 blockade fit in HL therapy?

Alex F. Herrera
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 213–220.
https://doi.org/10.1182/asheducation-2018.1.213
Published: 2018
Journal Articles

Risk-adapted therapy for advanced-stage Hodgkin lymphoma

Michael A. Spinner, Ranjana H. Advani
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 200–206.
https://doi.org/10.1182/asheducation-2018.1.200
Published: 2018
Journal Articles

Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy

Alison J. Moskowitz
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 207–212.
https://doi.org/10.1182/asheducation-2018.1.207
Published: 2018
Journal Articles

Harnessing the power of the immune system in non-Hodgkin lymphoma: immunomodulators, checkpoint inhibitors, and beyond

Stephen M. Ansell
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 618–621.
https://doi.org/10.1182/asheducation-2017.1.618
Published: 2017
Journal Articles

Primary mediastinal B-cell lymphoma: biology and evolving therapeutic strategies

Kieron Dunleavy
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 298–303.
https://doi.org/10.1182/asheducation-2017.1.298
Published: 2017
Journal Articles

Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma

W. Robert Liu, Margaret A. Shipp
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 310–316.
https://doi.org/10.1182/asheducation-2017.1.310
Published: 2017
Journal Articles

Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution

Nancy L. Bartlett
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 317–323.
https://doi.org/10.1182/asheducation-2017.1.317
Published: 2017
Journal Articles

Novel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma

Craig Moskowitz
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 331–338.
https://doi.org/10.1182/asheducation-2016.1.331
Published: 2016
Journal Articles

Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment

Flora E. van Leeuwen, Andrea K. Ng
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 323–330.
https://doi.org/10.1182/asheducation-2016.1.323
Published: 2016
Journal Articles

Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet?

Peter W. M. Johnson
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 316–322.
https://doi.org/10.1182/asheducation-2016.1.316
Published: 2016
Journal Articles

Hodgkin lymphoma in children and adolescents: improving the therapeutic index

Kara M. Kelly
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 514–521.
https://doi.org/10.1182/asheducation.V2015.1.514.3917878
Published: 2015
Journal Articles

Evens AM, Kostakoglu L. The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease. Hematology Am Soc Hematol Educ Program. 2014;2014: 135-143 .

Journal: Hematology
Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 652.
https://doi.org/10.1182/asheducation.V2015.1.652.3918153
Published: 2015
Journal Articles

Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era

Solomon A. Graf, Ajay K. Gopal
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 151–157.
https://doi.org/10.1182/asheducation-2014.1.151
Published: 2014
Journal Articles

The classical Hodgkin lymphoma tumor microenvironment: macrophages and gene expression-based modeling

David W. Scott, Christian Steidl
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 144–150.
https://doi.org/10.1182/asheducation-2014.1.144
Published: 2014
Journal Articles

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease

Andrew M. Evens, Lale Kostakoglu
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 135–143.
https://doi.org/10.1182/asheducation-2014.1.135
Published: 2014
Journal Articles

Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects

Andrea K. Ng
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 488–494.
https://doi.org/10.1182/asheducation-2014.1.488
Published: 2014